What is Zacks Research’s Estimate for CORT FY2025 Earnings?

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Investment analysts at Zacks Research lowered their FY2025 earnings per share (EPS) estimates for Corcept Therapeutics in a note issued to investors on Tuesday, November 25th. Zacks Research analyst Team now expects that the biotechnology company will post earnings of $0.91 per share for the year, down from their previous estimate of $1.09. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q4 2025 earnings at $0.29 EPS, Q1 2026 earnings at $0.04 EPS, Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.32 EPS, Q1 2027 earnings at $0.55 EPS, Q2 2027 earnings at $0.72 EPS, Q3 2027 earnings at $0.95 EPS and FY2027 earnings at $3.35 EPS.

Several other research analysts have also recently weighed in on CORT. Wall Street Zen cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, October 18th. HC Wainwright reiterated a “buy” rating and set a $145.00 target price on shares of Corcept Therapeutics in a research note on Tuesday. Piper Sandler dropped their price target on Corcept Therapeutics from $131.00 to $121.00 and set an “overweight” rating on the stock in a research note on Friday, August 1st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Corcept Therapeutics in a report on Wednesday, November 19th. Finally, Wolfe Research initiated coverage on Corcept Therapeutics in a research report on Tuesday, November 18th. They set a “peer perform” rating for the company. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $135.25.

Corcept Therapeutics Price Performance

Shares of NASDAQ:CORT opened at $79.80 on Wednesday. The company has a market cap of $8.39 billion, a P/E ratio of 70.62 and a beta of 0.43. The stock’s fifty day moving average price is $78.26 and its 200-day moving average price is $74.07. Corcept Therapeutics has a 1 year low of $49.00 and a 1 year high of $117.33.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.02). The firm had revenue of $207.64 million during the quarter, compared to analysts’ expectations of $223.78 million. Corcept Therapeutics had a return on equity of 20.10% and a net margin of 18.51%.The firm’s quarterly revenue was up 13.8% on a year-over-year basis. During the same period last year, the firm posted $0.41 earnings per share. Corcept Therapeutics has set its FY 2025 guidance at EPS.

Insider Activity

In other Corcept Therapeutics news, insider William Guyer sold 20,000 shares of Corcept Therapeutics stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $70.49, for a total transaction of $1,409,800.00. Following the transaction, the insider owned 5,487 shares of the company’s stock, valued at $386,778.63. The trade was a 78.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Joseph K. Belanoff sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $85.08, for a total transaction of $3,403,200.00. Following the completion of the transaction, the chief executive officer owned 2,781,370 shares of the company’s stock, valued at approximately $236,638,959.60. The trade was a 1.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 263,900 shares of company stock valued at $20,373,338 in the last ninety days. Corporate insiders own 20.80% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CORT. Dimensional Fund Advisors LP lifted its position in shares of Corcept Therapeutics by 2.8% in the first quarter. Dimensional Fund Advisors LP now owns 2,136,510 shares of the biotechnology company’s stock valued at $243,708,000 after acquiring an additional 57,942 shares in the last quarter. AQR Capital Management LLC boosted its stake in Corcept Therapeutics by 546.9% in the 3rd quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock worth $125,264,000 after purchasing an additional 1,274,215 shares during the period. Invesco Ltd. grew its holdings in Corcept Therapeutics by 76.5% during the 1st quarter. Invesco Ltd. now owns 1,246,234 shares of the biotechnology company’s stock valued at $142,345,000 after buying an additional 540,101 shares in the last quarter. Northern Trust Corp grew its holdings in Corcept Therapeutics by 0.6% during the 1st quarter. Northern Trust Corp now owns 1,022,001 shares of the biotechnology company’s stock valued at $116,733,000 after buying an additional 6,486 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Corcept Therapeutics during the second quarter valued at approximately $72,048,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.